Investing.com - Dr. Reddy’s Labs ADR (NYSE: RDY) reported second quarter EPS of $1.07, $0.19 better than the analyst estimate of $0.88. Revenue for the quarter came in at $828M versus the consensus estimate of $815.95M.
Dr. Reddy’s Labs ADR's stock price closed at $64.60. It is down -6.12% in the last 3 months and up 16.88% in the last 12 months.
Dr. Reddy’s Labs ADR saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Dr. Reddy’s Labs ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Dr. Reddy’s Labs ADR's Financial Health score is "great performance".
Check out Dr. Reddy’s Labs ADR's recent earnings performance, and Dr. Reddy’s Labs ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar